文献速递甲状腺核医学核素与放射性配体治疗

放射性碘消融甲状腺残余组织治疗Graves眼病患者

Radioiodine Ablation of Thyroid Remnants in Patients with Graves' Orbitopathy.
PubMed 文献 · J Nucl Med · 2022-11-23

本回顾性研究分析30例甲状腺次全切除术后不稳定Graves眼病患者,行放射性碘消融甲状腺残余组织。消融后3个月和12个月临床活动度评分、NOSPECS及软组织炎症评分显著下降,90%患者3个月后GO不活动,97%患者12个月后不活动,无新发GO活化。

要点

  • 甲状腺次全切除术后不稳定GO患者行放射性碘消融残余组织后,12个月临床活动度评分从3.4降至1.3(P<0.0001)。
  • 消融后3个月90%(27/30)患者GO不活动,12个月达97%(29/30),无新发GO活化。
  • 残余体积、促甲状腺激素受体抗体滴度和99mTc摄取在消融后3个月内显著下降。

核心结论

  • 甲状腺切除术后放射性碘治疗可成功消融残余甲状腺组织,改善GO、降低炎症活动并稳定甲状腺功能。
  • 作者认为,对甲状腺切除术后不稳定GO患者应考虑行闪烁显像以排除甲状腺残余组织。

研究设计与样本

  • 回顾性研究,纳入30例甲状腺次全切除术后不稳定Graves眼病患者,其中轻度4例(13%)、中重度25例(83%)、极重度1例(3%)。
  • 主要终点为消融后3个月和12个月时GO相关症状改善,采用临床活动度评分、NOSPECS和软组织炎症评分评估。
  • 消融成功定义为消融后3个月甲状腺闪烁显像99mTc摄取下降、残余体积减小及促甲状腺激素受体抗体水平下降。

主要发现

  • 消融后12个月,临床活动度评分从3.4降至1.3(P<0.0001),NOSPECS从5.9降至4.9(P=0.007),软组织炎症评分从4.7降至2.1(P=0.0001)。
  • 消融后3个月27/30(90%)患者GO不活动,12个月29/30(97%)患者GO不活动,无新发GO活化。
  • 消融后3个月内,残余体积从1.4 cm³降至0.4 cm³(P<0.0001),平均促甲状腺激素受体抗体滴度从19.02 IU/L降至13.37 IU/L(P<0.0001)。
  • 99mTc摄取从0.5%降至0.1%(n=12,P=0.04)。

临床怎么用

  • 作者认为,甲状腺切除术后不稳定GO患者应考虑行闪烁显像以排除甲状腺残余组织。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to assess response after ablation of thyroid remnants (ATR) with radioactive iodine therapy in patients with unstable Graves' orbitopathy (GO) after subtotal thyroidectomy. Methods: Thirty patients with mild (n = 4, 13%), moderate-to-severe (n = 25, 83%), or very severe GO (n = 1, 3%) were analyzed in this retrospective study. The primary endpoint was the improvement of GO-related symptoms as assessed by clinical activity scores, NOSPECS, and soft-tissue inflammation scores at 3 and 12 mo after ATR. Ablation success was defined by a decrease in 99mTc uptake on thyroid scintigraphy, remnant volume, and thyrotropin receptor antibody levels at 3 mo after ATR. Results: Twelve months after ATR, clinical activity scores, NOSPECS, and soft-tissue inflammation scores showed a significant decrease from 3.4 to 1.3 (P < 0.0001), 5.9 to 4.9 (P = 0.007), and 4.7 to 2.1 (P = 0.0001), respectively. The GO was inactive in 27 of the 30 (90%) patients after 3 mo and in 29 (97%) after 12 mo. No new activation of GO occurred. Remnant volume (1.4 vs. 0.4 cm3, P = <0.0001), mean thyrotropin receptor antibody level titer (19.02 vs. 13.37 IU/L, P < 0.0001), and 99mTc uptake (0.5% vs. 0.1%; n = 12; P = 0.04) decreased significantly until 3 mo after ATR. Discussion: Radioactive iodine therapy after thyroidectomy can successfully ablate residual thyroid remnants, leading to an improvement in GO, a reduction in inflammatory activity, and stabilization of thyroid function. Thus, scintigraphy should be considered for patients with unstable GO after thyroidectomy to rule out thyroid remnants.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Oeverhaus M, Koenen J, Bechrakis N, et al. Radioiodine Ablation of Thyroid Remnants in Patients with Graves' Orbitopathy. J Nucl Med. 2022. PMID: 36418167. doi:10.2967/jnumed.122.264660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。